Réaction #599

ord-74a05ca9ab9042dbb66a38d995757deb

Équation de réaction

Cc1nn(-c2ccnc(Cl)n2)cc1CN1CC(O)C1
Cc1nn(-c2ccnc(Cl)n2)
Cc1c(Cl)c2cc(N)ccc2n1C
Cc1c(Cl)c2cc(N)ccc2n
Cc1nn(-c2ccnc(Nc3ccc4c(c3)c(Cl)c(C)n4C)n2)cc1CN1CC(O)C1
Cc1nn(-c2ccnc(Nc3ccc

Solvants

Conditions de réaction

Température
100°CELSIUS

Mode opératoire

A 40 mL scintillation vial charged with 3-chloro-1,2-dimethyl-1H-indol-5-amine (53.6 mg, 0.28 mmol), 1-((1-(2-chloropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)azetidin-3-ol (70mg, 0.25 mmol), palladium(II) acetate (2.81 mg, 0.01 mmol), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (x--phos) (11.93 mg, 0.03 mmol) and Dioxane (3 mL) After being degassed by nitrogen bubbling , the reaction mixture was heated to 100 °C for 5 hours. LCMS analysis indicated no desired product and chloropyrimidine starting material was decomposed. The reaction mixture was discarded. Need to reverse the sequence.

Source

750 AstraZeneca ELN dataset